Article
Belimumab promotes negative selection of activated autoreactive B cells in systemic lupus erythematosus patients.
JCI insight - 6 Sept 2018
Huang Weiqing, Quach Tam D, Dascalu Cosmin, Liu Zheng, Leung Tungming, Byrne-Steele Miranda, Pan Wenjing, Yang Qunying, Han Jian, Lesser Martin, Rothstein Thomas L, Furie Richard, Mackay Meggan, Aranow Cynthia, Davidson Anne
Abstract excerpt
Belimumab has therapeutic benefit in active systemic lupus erythematosus (SLE), especially in patients with high-titer anti-dsDNA antibodies. We asked whether the profound B cell loss in belimumab-treated SLE patients is accompanied by shifts in the immunoglobulin repertoire. We enrolled 15 patients who had been continuously treated with belimumab for more than 7 years, 17 matched controls, and 5 patients who...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.